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Background: Surgical wounds healing by secondary intention (SWHSI) are increasingly being treated
with negative-pressure wound therapy (NPWT) despite a lack of high-quality research evidence regarding
its clinical and cost-effectiveness. This pilot feasibility RCT aimed to assess themethods for and feasibility
of conducting a future definitive RCT of NPWT for the treatment of SWHSI.
Methods: Eligible consenting adult patients receiving care at the study sites (2 acute and 1 community)
and with a SWHSI appropriate for NPWT or wound dressing treatment were randomized 1 : 1 centrally
to receive NPWT or usual care (no NPWT). Participants were followed up every 1–2weeks for 3months.
Feasibility (recruitment rate, time to intervention delivery) and clinical (time to wound healing) outcomes
were assessed.
Results: A total of 248 participants were screened for eligibility; 40 (16⋅1 per cent) were randomized, 19
to NPWT and 21 to usual care. Twenty-four of the 40 wounds were located on the foot. Participants
received NPWT for a median of 18 (range 0–72) days. Two participants in the NPWT group never
received the intervention and 14 received NPWT within 48h of randomization. Five participants in the
usual care group received NPWT during the study. Ten of the 40 wounds were deemed to have healed
during the study.
Conclusion: A full-scale RCT to investigate the clinical and cost-effectiveness of NPWT for SWHSI is
feasible. This study identified crucial information on recruitment rates and data collection methods to
consider during the design of a definitive RCT.
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Introduction
The UK National Health Service (NHS) undertakes a
substantial number of surgical operations every year, with
most involving an incision1 that is closed with sutures or
staples while healing occurs (healing by primary intention).
Surgical wounds, however, may dehisce or be left open
intentionally to heal ‘from the bottom up’ through forma-
tion of granulation tissue (healing by secondary intention).
The management of surgical wounds healing by secondary
intention (SWHSI) can be challenging as wounds may
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remain open for many months and/or require multiple
additional treatments2. As a result, there may be a signifi-
cant financial burden to the NHS and a substantial impact
on patients’ quality of life.
Existing literature focuses on guidance for the manage-
ment of SWHSI; however, there is little published evidence
regarding SWHSI treatment (such as type and frequency
of dressings used) or wound healing rates attributable to
specific treatments. Systematic reviews3,4 have identified
a limited number of trials assessing the effects of various
treatments. Many of the trials were small and of poor qual-
ity, and there is little evidence to suggest that any specific
treatment improves wound healing. Given the limited clin-
ical and cost-effectiveness evidence for existing treatments,
the National Institute for Health and Care Excellence in
the UK has identified RCTs of SWHSI treatments as a key
research priority5.
In recent years advanced and costly treatments, such
as negative-pressure wound therapy (NPWT), have been
used increasingly as treatments for SWHSI. It is claimed
that NPWT, used as part of the treatment pathway,
rather than to the point of healing, may have a positive
effect on wound healing by removing exudate, reduc-
ing infections and increasing tissue perfusion6. There
is, however, limited high-quality research evidence to
support the use of NPWT. A recent systematic review7
assessing NPWT as a treatment for non-abdominal
SWHSI identified only two RCTs (69 total participants),
both of which reported limited outcome data. Clini-
cal and cost-effectiveness modelling using observational
data (P. Saramago et al., unpublished data, 2018) showed
that, even after adjustment for intergroup differences,
NPWT was associated with prolonged time to healing
and was highly unlikely to be cost-effective. It is estimated
(P. Saramago et al., unpublished data, 2018) that cessation
of NPWT would save the NHS between €212 and €407
(£171 and £328) million per annum (exchange rate at
2014 prices8: £1 = €1⋅24). As these findings are based on
observational data, they must be interpreted with caution.
Given that NPWT is used widely for SWHSI within
the NHS, high-level evidence investigating its clinical
and cost-effectiveness is required urgently. Recruitment
to NPWT trials can be difficult9,10, so the aim of this
pilot study was to assess the methods for, and feasibility
of, conducting a definitive adequately powered RCT of
NPWT for SWHSI.
Methods
Full details of the trial protocol have been published
elsewhere11 and are given in brief below. A two-armed,
parallel-group, pilot feasibility RCT was conducted,
recruiting participants from acute and community settings
in Hull and Leeds, UK.
Patients receiving care for a SWHSI from Hull and East
Yorkshire Hospitals NHS Trust, Leeds Teaching Hospitals
NHS Trust and Leeds Community Healthcare NHS Trust
were screened against eligibility criteria by the direct care
team (Table 1). Potentially eligible participants were pro-
vided with an information sheet to consider for at least 24 h
before being approached by the study research nurse for
written informed consent.
Ethical approval for this study was granted by Yorkshire
andHumber–Leeds East Research Ethics Committee (ref-
erence 15-YH-0307) and by the associated NHS trusts.
Intervention group: negative-pressure wound
therapy
NPWT devices that were being employed in the acute and
community services inHull and Leeds were selected for use
in this study. Eligible NPWT devices were V.A.C.® (KCI,
San Antonio, Texas, USA), Renasys® (Smith & Nephew,
Hull, UK) and PICO® (Smith & Nephew). The choice
of device and duration of the therapy were decided by
the clinical care team in conjunction with the participant.
Aspects of the NPWT treatment regimen, such as pressure
cycles and dressing change frequency, were according to
the standard practice at the time.The only stipulationmade
for NPWT use was that it must be clinically appropriate.
When not being treated withNPWT, participants’ wounds
received usual care. The type of device, dressings and
pressure cycles were recorded, and any changes reported
at subsequent follow-up visits.
Comparator group: usual care
Control group participants received usual care (wound
dressings, no NPWT). The type of dressing used was not
stipulated for the trial as there is no evidence to suggest that
any one dressing is more clinically or cost-effective than
another3. The most appropriate dressings and frequency
of dressing change were selected by the clinical care team
and recorded throughout the trial.
Baseline data and follow-up visits
Participant demographics, wound and surgery characteris-
tics, and participant self-reported questionnaires (assessing
quality of life and pain scores) were collected at the base-
line visit. Where participants had more than one SWHSI,
the largest wound was deemed the ‘reference’ wound, and
data were collected for this wound during the study.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
Aged 18 years and over and able to give full informed consent
A SWHSI that could be reasonably treated with NPWT or wound dressings
A SWHSI that was considered ready for NPWT (minimum 80% viable tissue or thin layer of slough requiring no further debridement)
Receiving adequate nutrition (as assessed by senior nurse responsible for nursing care)
Exclusion criteria
Unable to give informed consent
With limited life expectancy (for example undergoing end-stage palliative care)
Presence of an active systemic infection
Had already received NPWT on current SWHSI
Currently receiving NPWT or received NPWT while in theatre for the operation resulting in their SWHSI
Inadequate haemostasis or at risk of bleeding
Chronic wound (such as pressure or foot ulcers) that was non-surgical in origin but that had been surgically debrided (a distinctly different subgroup)
Unwilling to have wound photographs taken
Current or previous (in the previous 4weeks) participant in a research study
Presence of any of the following wound characteristics
Unclear undermining in the wound cavity precluding use of NPWT
Necrotic tissue or eschar
Malignant tissue
Exposed blood vessels and/or organs, anastomotic sites and/or nerves (including cases where abdominal fascia was open)
Located where a vacuum seal could not be obtained (in the opinion of the treating clinician)
SWHSI, surgical wound healing by secondary intention; NPWT, negative-pressure wound therapy.
After randomization, participants were followed up for a
maximum of 3months unless they withdrew consent, died
or were lost to follow-up. Clinical data were collected by
research nurses on aweekly to fortnightly basis at follow-up
assessment visits. The timing of clinical follow-up was not
standardized (beyond weekly to fortnightly) to allow the
feasibility of visit frequency to be assessed. Visits continued,
up to a maximum of three visits, following an assessment
that deemed the wound to have healed.
Feasibility
Feasibility outcomes included: eligibility rates (calculated
by dividing the number of people who met eligibility crite-
ria by the number screened for eligibility) and reasons for
ineligibility; participation rates (calculated by dividing the
number of participants randomized by the number of peo-
ple eligible for the study) and reasons for non-participation;
withdrawal rates (calculated by dividing the number of
participants who withdrew from the study by the num-
ber recruited) and the reasons for withdrawal; ability to
deliver the intervention, including time between random-
ization and treatment; reasons for delays in start of treat-
ment; duration of NPWT use; reasons for NPWT ces-
sation; and treatment crossover. The need for training to
deliver NPWT was assessed via a questionnaire completed
by research nurses at the end of the study.
The trial protocol advised that a photograph of the
wound be taken at each assessment visit. Research staff
were provided with brief guidance on taking these photo-
graphs, which stipulated that the entire wound should be
in view and the participant identification be included in
the image. The feasibility of blinded outcome assessment
of healing and treatment allocation was assessed by pro-
viding blinded assessors with copies of the wound photo-
graphs and asking them to confirm whether: they deemed
the wound to be healed (full wound epithelialization); and
they believed they knew the participant’s treatment alloca-
tion. However, in practice it was not feasible for the blinded
reviewers to assess all participant wound photographs. It
was therefore decided that the last photograph taken after
randomization for each participant would be used in the
feasibility of blinded assessment of healing. Blinding to
treatment allocation was assessed using photographs taken
at week 1, as the final photograph may not reflect the orig-
inally allocated treatment given that NPWT is not neces-
sarily used to the point of wound healing.
Finally, the feasibility of collecting wound pain data
scored on a scale from 0 (no pain) to 10 (worst pain imag-
inable) using weekly text messages was assessed.
Clinical outcomes
Healing
The primary clinical outcome in a definitive trial would
be time in days from randomization to wound heal-
ing. Healing was assessed at each follow-up visit by the
research nurse and, when observed, the date of healing was
recorded.
Wound size
The wound area at baseline and at each follow-up visit was
calculated using ruler measurements: without adjustment
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(length × width); and with adjustment, by multiplying the
area by π/4 (length × width × 0⋅785)12. In addition, where
possible, a wound tracing was taken at the same time and
the area measured using Mouseyes software (R. Taylor,
Manchester, UK)13.
Health-related quality of life and pain
Participants self-completed questionnaires at baseline,
2weeks, and 1 and 3months after randomization.
Follow-up questionnaires were posted with a stamped
addressed envelope for return to the clinical trials unit.
Questionnaires included two generic health-related
quality-of-life (HRQoL) instruments, Short Form 12
(SF-12®; Quality Metric, Lincoln, Rhode Island, USA)
and EQ-5D-3L™ (EuroQol Group, Rotterdam, The
Netherlands), and three pain assessment instruments: a
visual analogue scale (VAS) for wound pain, and a VAS for
pain experienced when wound dressings were changed,
both scored from 0 (no pain) to 10 (worst pain imaginable),
and the nine-item short form of the Brief Pain Inventory
(BPI)14. The BPI comprises two subscales: average pain
severity, scored from 0 (no pain) to 10 (pain as bad as you
can imagine); and level of interference with mood and
daily activities caused by pain, scored from 0 (does not
interfere) to 10 (interferes completely).
Clinical and adverse events
Data were collected on clinical events (such as duration of
hospital stay and wound infection) and adverse events (both
serious and non-serious) throughout the trial.
Cost-effectiveness
This was explored using total mean resource use
cost and mean quality-adjusted life-year (QALY) per
trial arm.
Sample size
As this was a pilot trial, and the primary objective was to
determine measures of feasibility and acceptability rather
than to detect a treatment effect, a formal power calculation
was not conducted. The study aimed to randomize approxi-
mately 50 patients in order to assess eligibility, participation
and withdrawal of participants.
Randomization and blinding
Consenting participants were assigned 1 : 1 randomly to
receive either the intervention (NPWT) or usual care
(no NPWT). The randomization sequence was prepared
by the trial statistician (who was not involved in study
recruitment) using random permuted blocks of size 4 and
6 with stratification by wound area (less than 28 cm2 or
28 cm2 or more). Wound area was found to be associated
with wound healing in an earlier cohort study conducted by
the trial team (I. Chetter et al., unpublished data, 2018), in
which the median wound size among patients who received
NPWT was 28 cm2. The use of mixed block sizes, without
stratification by site, reduced predictability of allocation.
Allocations were concealed through a central random-
ization service implemented by an independent member
of staff at the York Trials Unit, University of York. Once
a patient had been consented, researchers telephoned the
York Trials Unit to obtain the treatment allocation. Owing
to the nature of the intervention, it was not possible to blind
participants or healthcare professionals to trial treatment.
Statistical analysis
Data analysis was conducted in Stata® version 13 (Stat-
aCorp, College Station, Texas, USA) using the principle
of modified intention-to-treat on an available case basis.
As this was a pilot trial, analyses are mainly descriptive in
nature, with summary statistics presented overall and by
trial arm according to participants’ original treatment allo-
cation, where data are available.
Time to healing was assessed using Kaplan–Meier curves
and the log rank test, recognizing that the study was not
powered to detect a treatment effect, and that this was
not a trial objective. Cox proportional hazards regression
was used to investigate the impact of co-variables shown
to be important in an earlier SWHSI cohort, including
contamination level of surgery, duration of wound in days
(time from surgery that resulted in SWHSI to random-
ization), and presence of infection at baseline (I. Chet-
ter et al., unpublished data, 2018). The stratification factor
(baseline wound size), in its continuous form as opposed
to being dichotomized, was also used as a co-variable in
the Cox model. The effects of SWHSI history, location
of SWHSI on the body, and infection at any time dur-
ing follow-up (as a time-dependent co-variable) were also
explored by including these, in turn, in the adjusted Cox
model.
Bland–Altman plots15 were used to assess agreement of
the measurement methods for wound size (ruler versus
tracings) used in the study.
Results
Recruitment commenced at Hull and East Yorkshire Hos-
pitalsNHSTrust on 20November 2015, at LeedsTeaching
Hospitals NHS Trust on 9 February 2016, and at Leeds
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Ineligible n=185 (reasons not mutually exclusive)
 Had already received NPWT on SWHSI n=68
 NPWT during surgery resulting in SWHSI n=31
 Could not receive intervention n=29
 Unclear undermining in wound cavity n=13
 Wound situated where vacuum seal could not be obtained n=13
 Unable to consent n=12
 Wound involved exposed blood vessels, organs, anastomotic sites
 and/or nerves n=11
 Systemic infection n=7
 Receiving inadequate nutrition n=5
 Limited life expectancy n=5
 Necrotic tissue or eschar present n=5
 Unwilling to have photographs taken n=5
 Haemostasis and/or risk of bleeding n=4
 Receiving care out of area n=2
 Participated in research in past 4 weeks n=2
 No SWHSI n=1
 Aged more than 18 years n=1
 Other reason n=48
Did not consent n=22
 Did not want NPWT n=5
 Did not want to participate in research n=3
 Preference for NPWT n=3
 Preference for standard treatment n=3
 Did not want to delay discharge n=2
 Wound close to healing n=2
 Other health issue n=1
 No reason given n=3
Allocated to usual care n=21
Received NPWT over course of follow-up n=5
 Improved exudate management and reduced
  frequency of dressing change n=1
 Wound deterioration n=2
 Wound bed prepared n=1
 Wound not progressing n=1 
Participant questionnaire return rate
 Week 2 n=18 of 21
 Month 1 n=16 of 20
 Withdrew from trial n=1
 Month 3 n=15 of 19
 Withdrew from trial n=1
Randomized in error (already received
NPWT on SWHSI) n=1
Allocated to NPWT intervention n=19
Received allocated intervention n=17
Did not receive intervention n=2
 Application of NPWT would have delayed discharge
 from hospital n=1
 Discharged into care of community practice nurses
 so unable to be treated with NPWT n=1
Participant questionnaire return rate
 Week 2 n=15 of 19
 Month 1 n=15 of 19
 Month 3 n=16 of 19
Analysed n=19 Analysed n=21
Fig. 1 CONSORT diagram depicting the flow of participants through the trial. NPWT, negative-pressure wound therapy; SWHSI,
surgical wound healing by secondary intention
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Community Healthcare NHS Trust on 3 March 2016, and
ran for a total of 7months, closing at all sites on 30 June
2016. Follow-up continued for a further 3months, until 30
September 2016.
Delays in receipt of local research and development
approvals were observed for two sites, owing to circum-
stances within the local trusts beyond the control of the
research team.This affected the recruitment rate in the first
3months of the trial; however, after the opening of all three
recruitment sites, the study achieved the recruitment tar-
get (7 participants per month) in the remaining 4months
of recruitment. In total, 41 participants were randomized
into the trial. One participant was subsequently found to
be ineligible, as they had previously received NPWT on
their SWHSI. Data for this participant were excluded from
all data summaries and analysis as they were randomized in
error. Thus, 40 eligible participants were randomized, 19
to NPWT and 21 to usual care. The flow of participants
through the trial is shown in Fig. 1.
Baseline characteristics
Baseline characteristics were similar in the two groups
(Table 2). The mean age of participants was 57⋅8 (range
33–88) years, and 22 were men. Wounds were commonly
located on the foot (24 patients); the initial indication had
been partial foot or toe amputation for 20 patients, debride-
ment of a non-chronic wound on the foot for two, and
abscess drainage for two. Thirteen wounds were reported
as being infected at baseline. Twenty-four participants had
diabetes. Participants allocated to usual care tended to have
had their wounds for longer than those allocated toNPWT
(median 12 versus 7 days respectively), and had a higher
incidence of wound infection (8 of 21 (38 per cent) versus 5
of 19 (26 per cent)), as assessed by clinicians against a pre-
defined features list (Appendix S1, supporting information).
Feasibility outcomes
Eligibility rate
Of the 248 patients screened, 63 (25⋅4 per cent) were
found to be eligible. Common reasons for ineligibility
included having already or previously received NPWT on
the SWHSI (99 of 185 ineligible patients, 53⋅5 per cent),
which was often applied in theatre at the time of surgery (31
patients), and the wound not being suitable forNPWT (29,
15⋅7 per cent).
Participation rate
Of the 63 eligible patients, 41 (65 per cent) consented
to participate in the trial. A variety of reasons for
Table 2 Baseline characteristics of randomized participants by
treatment group
NPWT
(n = 19)
Usual
care (n = 21)
Total
(n = 40)
Age (years)* 58⋅8(15⋅1) 56⋅9(13⋅9) 57⋅8(14⋅4)
Sex ratio (M : F) 11 : 8 11 : 10 22 : 18
BMI (kg/m2)* 29⋅2(5⋅6) 29⋅0(6⋅0) 29⋅1(5⋅7)
Diabetes 12 12 24
Peripheral arterial disease 7 7 14
Tobacco use
None 13 10 23
Ex-smoker 1 6 7
Current (≤ 1 pack/day) 2 4 6
Current (> 1 pack/day) 3 1 4
Previous history of SWHSI
Yes 5 5 10
No 11 15 26
Unknown 3 1 4
Wound area (cm2)† 18⋅2 (0⋅2–122⋅5) 20⋅4 (2⋅3–93⋅2) 19⋅3 (0⋅2–122⋅5)
< 28 10 11 21
≥ 28 9 10 19
Wound duration (days)† 7 (0–27) 12 (1–142) 7 (0–142)
Wound infected
Yes 5 8 13
No 14 13 27
Wound location
Foot 11 13 24
Abdomen 3 3 6
Leg 3 1 4
Breast 1 1 2
Groin 0 2 2
Buttocks 0 1 1
Perianal area 1 0 1
Type of surgery‡
Elective 12 18 30
Emergency 6 3 9
Contamination level of surgery
Clean 6 2 8
Clean-contaminated 9 12 21
Contaminated 4 7 11
Values are *mean(s.d.) and †median (range). ‡Type of surgery not known
for one patient in the negative-pressure wound therapy (NPWT) group.
non-participation were observed, the most common
(5 of 22 patients, 23 per cent) being that the patient did
not wish to receive NPWT.
Withdrawal rates and retention of participants
Of the 40 eligible randomized participants, two were
fully withdrawn from the trial due to amputation of the
reference wound (at 24 and 60 days after randomization),
equating to a withdrawal rate of 5 per cent (2 of 40). Both
participants were allocated to usual care. The study pro-
tocol was subsequently revised to enable continued data
collection from participants after amputation, provided
they continued to give consent. No further participants,
however, underwent amputation.
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Fig. 2 Kaplan–Meier curve of time from randomization to
healing in patients undergoing surgical wound healing by
secondary intention treated with negative-pressure wound
therapy (NPWT) or usual care. P = 0⋅418 (log rank test)
Participants received between one and 12 assessment vis-
its after randomization (median 8 in NPWT and 7 in
usual care group), with the first postrandomization assess-
ment occurring between 4 and 33 days (median 7⋅5 days in
NPWT and 9 days in usual care group). Overall, partici-
pant self-completed questionnaire response rates were at
least 78 per cent (31 of 40) at all time points.
Ability to deliver intervention
Of the 19 participants allocated to receive NPWT, two
never received the intervention. In one patient this was
because it would have delayed hospital discharge, and in
the other because a NPWT device was not available in the
community at the time. Ten participants received NPWT
within 24 h of randomization and 14 within 48 h. The
primary reason for delay (receiving NPWT 24h or more
after randomization) was the machine being unavailable (6
of the 7 remaining patients).
A Renasys® machine was applied in 12 of the 17 partic-
ipants who received NPWT, PICO® in four and V.A.C.®
in one patient. The pressure used ranged between 60 and
125 (median 80)mmHg, and was applied continuously in
all but one patient (PICO®; 80mmHg pressure applied
intermittently). In addition, two participants treated
with PICO® NPWT were reported to have had their
wounds packed with Aquacel® (Convatec, Reading, UK)
(hydrocolloid) and dressed with an Opsite® (Smith &
Nephew) (vapour permeable) dressing.
Participants in the intervention group received NPWT
for a median of 18 (range 0–72) days. Two of the 19
participants ceased NPWT therapy on the day of random-
ized treatment receipt due to a failure to maintain the seal.
Other reasons for discontinuation of NPWT included:
wound improving (8 patients) and wound healed, wound
deteriorated, wound bed prepared, wound too dry, wound
too small, wound edges bleeding, and blood in tubing of
canister (1 patient each).
Among the 21 participants receiving usual care,
hydrocolloid dressings were the most common initial
treatment (11 patients). Other initial dressings included
silver-containing dressings (3 patients), iodine-containing
dressings (3), basic dressings (3) and a soft polymer dressing
(1). Five participants in this group subsequently crossed
over from their initial dressing to NPWT, a median of 4
(range 0–17) days after randomization. Reasons for cross-
ing over included: improved exudate management and
reduced frequency of dressing change (1 patient; NPWT
commenced on day 0 after randomization), wound dete-
rioration (2 patients; commenced NPWT on day 4 and 6
after randomization), that the wound bed was prepared for
further treatments, for example skin grafting (1 patient;
day 3), and that wound healing was not progressing (1
patient; day 17). These five participants remained on
NPWT for a median of 31 (range 19–36) days. No other
participants in the usual care group were reported to have
had NPWT applied during the course of the trial.
Of the eight research nurses involved in the study, six
indicated that, as part of their role, they would apply
NPWT for study participants. Not all the nurses had the
opportunity to do this during the trial, but of those who
indicated they would have to apply NPWT to study par-
ticipants, four felt they had received sufficient training,
through their institutions, to apply this treatment confi-
dently. All eight research nurses completing the question-
naire indicated that not all of their colleagues had the
required knowledge and skills to use NPWT, and that spe-
cific standardized training in NPWT application would be
required as part of a definitive RCT.
Blinded outcome assessment of healing
Agreement on the assessment of wound healing status
(according to the final photograph taken of the wound) by
two initial reviewers was achieved for 29 (73 per cent) of the
40 participants (15 in the NPWT and 14 in the usual care
group). After assessment of the remaining 11 participants’
final photographs by a third reviewer, agreement between
two reviewers was reached for 38 participants (95 per cent),
but for two (both in the NPWT group) each reviewer
recorded a different judgement (healed, not healed, and
unsure). Where the reviewer was unsure and a reason for
this was provided (8 photographs), it was primarily due
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Fig. 3 Bland–Altman plots demonstrating the agreement between measurements from wound tracings and measurements of wound area
made using a a ruler and b an adjusted ruler. The difference between the two measurements made on the same observation (y-axis) is
plotted against the mean of the measurements (x-axis), and each is represented with a dot. The shaded area depicts the 95 per cent
agreement interval, within which 95 per cent of the differences fall. For example, the 95 per cent limits of agreement for plot a are
−11⋅3 to 25⋅6, indicating that for 95 per cent of observations a ruler measurement of wound area is between −11⋅3 and 25⋅6 cm2 larger
than a tracing measurement. This plot was produced using the batplot command in Stata®, with the notrend option
to poor photographic quality (4). Overall, eight of the
40 wounds (20 per cent) were judged by the assessors to
have healed (3 in the NPWT and 5 in the usual care
group); seven of these were also recorded as healed by the
investigators at the weekly to fortnightly visits. For three
additional wounds judged as healed by the investigators the
blinded assessors were either unsure of healing status or
there was discordance between all reviewers.
Assessors correctly identified treatment allocation
using the week 1 photograph for 15 of the 40 par-
ticipants (9 in the NPWT and 6 in the usual care
group). Allocation to NPWT was identified incorrectly in
six cases.
Collection of wound pain data using weekly text messages
Twenty-six participants (65 per cent, 13 in each group) con-
sented to be sent a weekly text message asking about their
pain, and 20 provided at least one response (10 in each
group). The majority of participants who responded pro-
vided at least four responses (19 of the 20 responders), and
eight responded to all text messages sent. The overall mean
pain score reduced between week 1 (mean(s.d.) 4⋅0(3⋅0))
and month 3 (mean(s.d.) 1⋅6(2⋅0)), although fluctuations in
scores were observed during this time interval (Table S1,
supporting information).
Clinical outcomes
Healing
Over the course of the trial, the wounds of ten (25 per
cent) of the 40 participants were deemed to have healed
based on the non-blinded research nurse assessments
at the weekly to fortnightly visits (6 in the NPWT
and 4 in the usual care group) (Fig. 2). Evidence from
the adjusted Cox proportional hazards models sug-
gested that wound size and duration were likely to be
associated with time to healing (Table S2, supporting
information).
Wound size
In general, wounds appeared to decrease in size in both
treatment groups at a similar rate over time (Table S3,
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Table 3 Short Form 12 Physical and Mental Health Composite
Scale scores
NPWT
(n = 19)
Usual care
(n = 21)
Total
(n = 40)
n Score* n Score* n Score*
Physical Composite Scale
Baseline 16 28⋅9(10⋅6) 19 34⋅9(11⋅4) 35 32⋅1(11⋅3)
Month 1 14 29⋅8(10⋅1) 15 38⋅8(12⋅1) 29 34⋅5(11⋅9)
Month 3 14 30⋅4(11⋅9) 14 42⋅8(8⋅3) 28 36⋅6(11⋅9)
Mental Health Composite
Scale
Baseline 16 44⋅7(12⋅6) 19 42⋅2(11⋅2) 35 43⋅3(11⋅8)
Month 1 14 42⋅7(13⋅8) 15 48⋅6(11⋅7) 29 45⋅8(12⋅9)
Month 3 14 41⋅5(10⋅9) 14 47⋅1(12⋅1) 28 44⋅3(11⋅6)
*Values are mean(s.d.). NPWT, negative-pressure wound therapy.
supporting information). The Bland–Altman plots indi-
cate that measurement of the wound using a ruler with-
out adjustment (length × width) overestimates wound area
compared with using the tracings (Fig. 3a). Adjusted wound
area measurement (length × width × 0⋅785) showed better
agreement with the tracings, but still tended to overesti-
mate the area (Fig. 3b). In both cases, overestimation tended
to increase with wound size.
Quality of life and pain
Improvement in the mean SF-12® Physical Compos-
ite Scale (PCS) score was observed over time in both
groups. The Mental Health Composite Scale (MCS) score
increased in the usual care group between randomization
and 1month, but decreased (worse health status) slightly at
the 3-month follow-up. In the NPWT group, MCS score
declined over time (Table 3).
In both groups there was minimal change in BPI severity
or interference, whereas VAS wound pain scores decreased
over time. In the NPWT group, VAS pain at dressing
changes peaked at 1month, whereas in the usual care group
it appeared to decrease over time (Table 4).
Clinical and adverse events
A total of 1135 dressing changes were completed during
the study (NPWT, 518; usual care, 617). The mean(s.d.)
number of dressing changes for NPWT participants was
27⋅26(18⋅91), and that for usual care participants was
29⋅38(14⋅38).
Wound infection was observed, through clinical review
against a predefined features list, in 17 participants
(NPWT, 6; usual care, 11). In total, 13 participants had a
wound infection reported at baseline; in nine the infection
resolved and did not reoccur (NPWT, 3; usual care, 6), and
in four the infection resolved but later reoccurred (NPWT,
2; usual care, 2). Four further participants developed an
Table 4 Pain scores by randomized group and time point
NPWT
(n = 19)
Usual care
(n = 21)
Total
(n = 40)
n Score* n Score* n Score*
BPI severity
Baseline 16 4⋅4(2⋅8) 20 2⋅7(2⋅8) 36 3⋅5(2⋅9)
Week 2 15 3⋅7(2⋅8) 17 2⋅5(2⋅5) 32 3⋅0(2⋅7)
Month 1 14 3⋅5(3⋅4) 15 1⋅9(2⋅6) 29 2⋅7(3⋅1)
Month 3 14 4⋅3(2⋅9) 13 2⋅1(2⋅6) 27 3⋅2(2⋅9)
BPI interference
Baseline 15 5⋅0(3⋅5) 16 2⋅8(3⋅6) 31 3⋅8(3⋅6)
Week 2 15 4⋅5(3⋅5) 17 3⋅3(3⋅3) 32 3⋅9(3⋅4)
Month 1 14 4⋅2(3⋅7) 15 2⋅3(2⋅8) 29 3⋅2(3⋅4)
Month 3 13 5⋅3(2⋅8) 15 2⋅7(3⋅4) 28 3⋅9(3⋅4)
VAS wound pain
Baseline 15 51⋅2(32⋅1) 18 34⋅8(32⋅7) 33 42⋅2(33⋅0)
Week 2 13 32⋅4(33⋅4) 17 26⋅5(29⋅3) 30 29⋅1(30⋅7)
Month 1 13 27⋅1(31⋅1) 14 20⋅7(26⋅7) 27 23⋅8(28⋅5)
Month 3 12 30⋅8(27⋅2) 15 13⋅5(23⋅1) 27 21⋅1(26⋅0)
VAS pain at dressing changes†
Week 2 13 22⋅3(25⋅5) 15 22⋅6(24⋅5) 28 22⋅5(24⋅5)
Month 1 13 26⋅5(32⋅8) 14 16⋅4(24⋅2) 27 21⋅2(28⋅5)
Month 3 11 18⋅1(20⋅2) 15 12⋅5(27⋅0) 26 14⋅8(24⋅1)
*Values are mean(s.d.). †Not measured at baseline. NPWT,
negative-pressure wound therapy; BPI, Brief Pain Inventory; VAS, visual
analogue scale.
infection at some point during their postrandomization
follow-up (NPWT, 1; usual care, 3).
Duration of hospital stay data were collected using
participant-reported questionnaires. Eight participants in
the NPWT group reported spending nights in hospital
during the trial (median 29 (range 2–60) nights). Only
one participant in the usual care group reported spending
nights in hospital (10 nights).
Five serious adverse events were reported, two in the
NPWT group from one participant, and three in the usual
care group from two participants. All events were related to
hospitalization (uncontrolled diabetes, 2; infected wound,
1; fall, 1; amputation due to osteomyelitis, 1), and only one
(usual care group; infected foot wound) was reported as
related to the reference wound. No events were deemed
to be definitely related to treatment received, but three of
the five events (amputation due to osteomyelitis, infected
wound and one instance of uncontrolled diabetes) were
possibly or probably related, all of which were expected.
There were no unexpected serious adverse events.
Twenty-eight non-serious adverse events were reported.
Themajority (25) were related to the reference wound, and
most (19) were reported as definitely related to treatment
(strong evidence that the event was caused by NPWT
device or usual care dressings). The most common event
type was ‘other’ (12 events), which included events such as
skin irritation (3), dressing falling off (3) and pump failure
(8).
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Table 5 Total mean costs per patient based on all available patients up to 3-month follow-up
NPWT Usual care
n Total cost (€)* n Total cost (€)* Incremental cost†(€)
Combined resource use 13096⋅20(10 137⋅48) 1591⋅15(2492⋅28) 11 505⋅06 (4569⋅36, 18 440⋅88)
Hospital outpatient clinic
Doctor 15 497⋅86(590⋅07) 13 140⋅11(212⋅33) 357⋅75 (2⋅25, 713⋅24)
Nurse 15 651⋅99(1012⋅78) 13 398⋅72(984⋅86) 253⋅27 (−525⋅63, 1032⋅18)
Day-case hospital visit 12 331⋅56(882⋅90) 14 213⋅14(797⋅50) 118⋅42 (−561⋅76, 798⋅59)
Nights as hospital inpatient 14 8672⋅98(9836⋅87) 11 450⋅54(1494⋅28) 8222⋅44 (2003⋅95, 14 440⋅93)
GP visit
At GP practice 14 82⋅40(164⋅32) 13 42⋅03(79⋅87) 40⋅37 (−63⋅37, 144⋅11)
At home 14 35⋅05(75⋅00) 13 0 35⋅05 (−7⋅84, 77⋅96)
Nurse visit
At GP practice 14 17⋅51(84⋅46) 12 122⋅65(228⋅33) −105⋅14 (−232⋅32, 22⋅05)
At home 14 218⋅47(316⋅24) 12 399⋅76(484⋅28) −181⋅29 (−507⋅74, 145⋅16)
*Mean(s.d.) costs converted from GBP to euros using the average yearly price level for 2015 (£1 sterling = €1⋅38)8. †Cost for negative-pressure wound
therapy (NPWT) minus cost for usual care; values in parentheses are 95 confidence intervals. GP, general practitioner.
Resource use and cost-effectiveness analysis
Participants in the NPWT group reported more hospital
care and general practitioner (GP) visits, but fewer nurse
visits (at surgery or home) in relation to the wound than
those in the usual care group; this was reflected in the
associated wound-related costs of each group (Table 5).
The mean(s.d.) total cost for the NPWT intervention was
€13 096⋅20(10 137⋅48) compared with €1591⋅15(2492⋅28)
for a patient under usual care (expressed in euros using
a 2015 price level of £1 sterling = €1⋅38)8. A large
proportion of the costs for patients in the NPWT
group were attributable to hospital care: mean(s.d.)
€10 639⋅80(10 428⋅66) versus €931⋅50(2517⋅12) for usual
care. Conversely, primary and community care costs were
lower for the NPWT group; for costs related to GP and
nurse visits, NPWT cost a mean of €291⋅18 (95 per cent
c.i. −611⋅34 to 27⋅60) less per patient in comparison with
usual care.
The baseline EQ-5D-3L™ score was lower (worse
HRQoL) for participants receiving NPWT (mean(s.d.)
0⋅34(0⋅10) versus 0⋅54(0⋅08) in the usual care group). At
3months, after adjustment for baseline utility, scores
had improved: scores were 0⋅49(0⋅35) and 0⋅77(0⋅23)
respectively. EQ-5D-3L™ data were missing for three
participants in the NPWT group, so could not be included
in the analyses. This, in combination with the small sample
size, accounts for differences in the mean scores between
the groups at baseline.
Participants who received NPWT had higher total NHS
and healthcare costs, and also achieved lower QALY gains
than those receiving usual care (complete case analysis: dif-
ference −0⋅007, 95 per cent c.i. −0⋅04 to 0⋅02). To account
for the levels of missing data observed for EQ-5D-3L™,
multiple imputation analysis was conducted; results were
similar to those for the complete case analysis (difference
−0⋅004, −0⋅03 to −0⋅02).
Discussion
This pilot study has provided invaluable information on the
feasibility of conducting a large-scale trial of NPWT for
the treatment of SWHSI.
After the opening of all sites to recruitment, the consis-
tent rate of recruitment observed indicates that it is possi-
ble to recruit participants to a trial of NPWT versus usual
care in this patient population. A full trial would, how-
ever, need to identify a sufficient number of recruiting sites.
For example, based on the recruitment rate observed (2
patients per site per month), a minimum of 11 study sites
would need to be opened to recruit 400 participants to
a similar trial over an 18-month period. Sample size cal-
culations would also need to consider the impact of (and
adjust accordingly for) the rates of participants allocated
to but not subsequently receiving NPWT (2 of 19 in the
present study) and usual care crossover rates (5 of 21 in this
study).
The majority of the 40 participants had a wound located
on the foot (24 patients, 60 per cent), probably because
this patient group was more readily able to be recruited
to this pilot feasibility study. Existing enthusiasm for
NPWT may have produced a lack of equipoise at the
study sites involved, with some health professionals being
unwilling to include their patients in the study. Thus,
some patient subgroups could not be recruited and are
under-represented in this sample. Careful engagement
of surgeons in advance of a full trial would be required
to ensure equipoise, and thereby promote recruitment.
The nature of engagement would depend on whether
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a homogeneous or heterogeneous study population was
proposed for inclusion in the trial.
The choice of study population for inclusion in a larger
trial would need to be considered carefully, given the
heterogeneity of the population of patients with SWHSI.
Even within subpopulations, for example those with foot
SWHSI, their heterogeneous nature must be considered.
Future trials should consider how best to balance ease
of recruitment, by including a heterogeneous popula-
tion, and comparability of data, by focusing on a smaller
subpopulation.
For this pilot feasibility study, the majority of partici-
pants were recruited in acute care settings, as this is where
patients with complex wounds are routinely cared for ini-
tially. A future RCT may therefore benefit from targeting
recruitment in acute care settings initially. The distribution
of participants in acute and community settings may dif-
fer between individual localities, so before recruitment it
would be necessary to ensure that appropriate recruitment
strategies and pathways were identified and implemented
at individual sites.
The most frequent reason for study ineligibility was
patients previously or currently receiving NPWT on their
SWHSI. A future trial should aim to recruit study sites
where there is sufficient equipoise in treatment of patients
with SWHSI; thus site evaluation before site inclusion
would be essential. Additionally, before undertaking a full
RCT, promotional activities with clinicians and research
groups to engage surgeons and nurses within the study
site would be valuable to ensure consistent and continued
referrals into the study. Such work may also help to allay
resistance to trial recruitment from certain clinical groups.
Anecdotal evidence from the sites in this pilot study sug-
gested some resistance to recruitment of patients by some
surgeons, either because NPWT was used primarily for
wound management, as opposed to healing, or due to sur-
geons’ prior experience of NPWT, leading them to believe
this treatment was inappropriate for use in a specific patient
group. Given the small number of sites included in this
pilot study, it is impossible to draw firm conclusions on
whether resistance amongst specific clinical groups would
be present in a larger RCT.
A participation rate of 65 per cent, participant-reported
questionnaire response rates in excess of 75 per cent, and
a limited number of withdrawals demonstrate that eligible
patients are willing to engage and commit to a RCT of
NPWT versus usual care.
During the study, only two of the 40 participants were
withdrawn from the trial, both due to amputation of the
reference wound. Data collection did not continue for
these participants, and the trial protocol was subsequently
amended to reflect that clinical data would cease at the
point of amputation. Participant-reported and resource
use data could continue to be collected, subject to contin-
ued consent, to capture the impact of limb amputation on
patient HRQoL and costs incurred. A future trial should
ensure that the process for continued data collection fol-
lowing amputation is clearly defined before commencing
study recruitment.
The movement of patients between acute and commu-
nity settings did not affect follow-up completion, with
follow-up continuing as planned in the majority of cases.
The research nurses did, however, note that on occasion
it was impossible to assess the wound at follow-up visits,
primarily as a result either of community healthcare pro-
fessionals (such as district nurses) having already attended
and redressed the wound or of community healthcare pro-
fessionals not attending at the agreed time for the visit, so
that research data could not be collected in full.
In general, participants received NPWT delivery within
48 h of randomization; however, three participants did not
receive NPWT within this time. Two participants did not
receive NPWT at all, due to lack of intervention availabil-
ity and potential for delays to discharge. The availability
of NPWT devices should be established at sites from the
outset of a future RCT to ensure timely delivery of the
intervention.
As evidence for the effectiveness of specific wound dress-
ings is limited, and often of low quality, the choice of dress-
ings for use as a comparator within a trial setting requires
consideration. Given the number of changes made to the
types of dressing used for individual patients in routine
care, and differences in guidelines and dressing availabil-
ity in individual NHS trust settings, it is likely to be dif-
ficult to standardize to a single dressing. It may therefore
be more pragmatic to consider permitting the use of any
dressing, or a specific range of dressing types, in a future
trial.
Treatment crossover was recorded for five of the 21
participants in the usual care group. In view of the impact
that crossover may have in relation to estimates of effect,
future trials should consider whether use of NPWT can be
minimized or prevented in the usual care arm. If it cannot
be prevented, appropriate statistical analysis should be used
to account for this crossover.
Nurses involved in the study reported that they had
received sufficient training within their individual insti-
tutions to apply NPWT confidently. They noted, how-
ever, that clinical colleagues were not always confident
in using NPWT, which corresponds to findings from a
recent qualitative study16. A future trial would therefore
need to ensure that NPWT training was provided to all
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staff who may administer trial treatment as part of the
study.
This study has demonstrated that collection of data
regarding future potential primary and secondary clini-
cal outcome measures is feasible; no major obstacles were
encountered. Given the limited number of participants
involved in this study, there was insufficient power to
enable any true treatment effect of NPWT to be assessed,
and, indeed, this was not the purpose of the study. The asso-
ciations between co-variables and wound healing obtained
using Cox proportional hazards regression should be inter-
preted with caution. A full RCT is required to assess fully
the clinical and cost-effectiveness of NPWT as a treatment
for patients with SWHSI.
Observational work (I. Chetter et al., unpublished data,
2018) preceding this pilot RCT identified a median time
to healing for all patients of 86 days. As a result it was
deemed that follow-up of 90 days might be sufficient to
observe wound healing. As only ten (25 per cent) of the 40
wounds healed during the course of this trial, a 3-month
follow-up is probably inadequate for reliable investigation
and comparison of healing rates. Follow-up for a mini-
mum duration of 6months would therefore need to be
considered for a larger trial.
The difference in time to healing found in this pilot
feasibility trial and a previous cohort study (I. Chetter
et al., unpublished data, 2018) may be explained by the
greater proportion of participants with foot and leg wounds
recruited to the trial (usually secondary to diabetes). The
differences in healing trajectory for specific wound types
and the complexities associated with wound healing in peo-
ple with diabetes17 may explain these lower healing rates.
The number of nights spent as an inpatient differed
between trial arms, and may be explained by regional
arrangements for the supply of NPWT to NHS patients
following discharge from the acute setting. These arrange-
ments may be specific to the participating sites involved
in the study, and not necessarily indicative of NHS-wide
processes. Tomitigate the impact of regional arrangements
on duration of inpatient stay, local discharge arrangements
in relation to patients using NPWT and availability of
NPWT within community settings should be discussed
as part of preliminary engagement with potential recruit-
ment sites. This will ensure that sufficient provisions are in
place at all recruiting sites and facilitate homogenization
of NPWT delivery across study sites. This is critical to
ensure the smooth delivery of a larger RCT and to pre-
vent significant differences in treatment delivery and cost
between study centres.
Assessment of wound measurements indicated that
ruler measurements, both with and without adjustment,
overestimate wound size compared with wound trac-
ings. Wound tracings are therefore recommended as the
primary source for wound measurement in a larger RCT.
This pilot trial has demonstrated the feasibility of blinded
outcome assessment of a single photograph in the context
of NPWT for SWHSI; the logistics of reviewing the full
photograph set for each patient were too complex. As a
result, it was not possible to derive time to healing through
the blinded outcome assessment.
Blinded and unblinded investigator assessment in rela-
tion to wound healing agreed in seven of eight cases,
although blinded assessment of healing was often ham-
pered by the quality of the wound photograph. Assessors
correctly identified NPWT allocation more frequently
than usual care; however, as overall identification of the
correct allocation was observed in only about one-third
of cases (15 of 40), blinded assessment can be deemed
to be feasible and appropriate within a future RCT.
Previous venous leg ulcer studies18,19 have used blinded
outcome assessment to assess wound-related outcomes
(time to wound healing, debridement status). These
studies demonstrated that remote blinded outcome assess-
ment can be completed successfully in wound-related
research assessing healing outcomes. A robust pho-
tography procedure should be implemented to ensure
consistency of imaging completion and return throughout
the study, and reliability of time-to-healing as an outcome
measure.
This pilot study has identified key elements and recom-
mendations for recruitment, data collection, outcomemea-
surement, trial design and safety reporting that should be
considered for a larger RCT to investigate the clinical and
cost-effectiveness of NPWT versus usual care in patients
with SWHSI. A full RCTwill aim to obtainmore definitive
evidence and so reduce the current uncertainty surround-
ing NPWT efficacy and cost-effectiveness.
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